Medtronic has obtained CE mark approval for its Hugo robotic-assisted surgery (RAS) system for use in urological and gynaecological procedures.
The system will now become commercially available in Europe.
Intended for use in an extensive range of surgical procedures, the Hugo RAS system is a modular, multi-quadrant platform equipped with three-dimensional (3D) visualisation and wristed instruments.
Hugo also has a Cloud-based surgical video recording option enabled through the Touch Surgery Enterprise.
The platform integrates these various features with specialised support groups that focus on the robotics programme, service and training.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Medtronic stated that the device was developed to address issues, such as cost and usage barriers, that have restricted the adoption of robotic surgery for the last 20 years.
The latest approval comes after the Hugo RAS system achieved certain milestones in its global launch, including the first urological and gynaecological procedures undertaken in India and Latin America.
Medtronic Europe, Middle East and Africa (EMEA) region executive vice-president and president Rob ten Hoedt said: “Robotics and artificial intelligence are the undeniable future of healthcare, with incredible potential to not only advance patient care but increase access to these benefits.
“The Hugo RAS system builds on our leadership in minimally invasive surgery, and we’re thrilled to provide hospitals across Europe a robotic-assisted surgery system that is thoughtfully designed to meet their needs today and tomorrow.”
Following the latest approval, the company now expects various hospitals in Europe to become a part of its Partners in Possibility Program, an initiative that allows them to use the Hugo system and participate in the international patient registry.
In August, the US Food and Drug Administration (FDA) approved Medtronic’s latest self-expanding transcatheter aortic valve replacement system to treat symptomatic severe aortic stenosis.